Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,11 USD | +7,65% | -3,22% | -20,98% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 2,78 mln. 2,58 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,31 mln. | Nettowinst (verlies) 2025 * | -26 mln. -24,09 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,16
x | K/w-verhouding 2025 * |
-0,09
x | Werknemers | 12 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 75,01% |
Recentste transcriptie over Cyclacel Pharmaceuticals, Inc.
1 dag | +7,65% | ||
1 week | -3,22% | ||
Lopende maand | -17,58% | ||
1 maand | -21,27% | ||
3 maanden | -25,71% | ||
6 maanden | -59,11% | ||
Lopend jaar | -20,98% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-01-02 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 83 | 01-03-06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 2,11 | +7,65% | 46 138 |
27-03-24 | 1,96 | +2,08% | 14 688 |
26-03-24 | 1,92 | -10,28% | 107 917 |
25-03-24 | 2,14 | -2,19% | 58 529 |
22-03-24 | 2,188 | +0,37% | 36 905 |
uitgestelde koers Nasdaq, 28 maart 2024 om 21:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-20,98% | 2,78 mln. | |
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-36,53% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |